Envas 5 Tablet

This mechanism also decreases the workload on the heart, improving cardiac output in patients with heart failure. Envas 5 Tablet is effective in reducing morbidity and mortality associated with congestive heart failure and is also used to prevent the progression of diabetic nephropathy by reducing intraglomerular pressure. The usual dosage should be individualized based on patient response and clinical condition, with close monitoring of blood pressure, renal function, and serum electrolytes, particularly potassium.

Common adverse effects include hypotension, dizziness, cough, hyperkalemia, and renal impairment. It is contraindicated in patients with a history of angioedema related to previous ACE inhibitor therapy and during pregnancy due to potential fetal toxicity. Envas 5 Tablet should be used cautiously in patients with renal artery stenosis or severe renal impairment. Regular follow-up and adherence to prescribed dosage are essential to optimize therapeutic outcomes and minimize risks.